Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting
- PMID: 40397510
- DOI: 10.1097/WAD.0000000000000656
Cerebrospinal Fluid Biomarkers and Cognition in Alzheimer Disease and Frontotemporal Dementia in a Memory Clinic Setting
Abstract
Objective: Currently available literature on the relationships between cerebrospinal fluid (CSF) biomarkers and cognitive performance in frontotemporal dementia (FTD) is very limited and inconclusive. In this study, we investigated the association of cognitive symptoms, as measured with Montreal Cognitive Assessment (MoCA), with CSF levels of total tau (t-tau), phosphorylated tau at threonine 181 (p-tau181), and amyloid β 1-42 (Aβ1-42) in a group of patients with probable FTD and Alzheimer disease (AD).
Methods: We conducted a retrospective cohort study with participants selected from the electronic records of patients seen at Yale New Haven Hospital's Memory Clinic, CT. A total of 61 patients, 28 with FTD (mean age=64.1) and 33 with AD (mean age=66.8), with available CSF results and cognitive test scores in their chart were included in analyses.
Results: T-tau levels negatively and significantly correlated with total MoCA scores as well as the different MoCA index scores in patients with FTD (r=-0.47, P=0.04). There were no significant associations between MoCA scores and p-tau181 levels in patients with FTD (r=-0.22, P=0.25). Patients with AD exhibited significant correlations between MoCA scores and both t-tau (r=-0.54, P<0.01) and p-tau (r=-0.55, P<0.01) levels. Also, Aβ1-42 levels were not significantly correlated with MoCA scores in either of the FTD and AD groups.
Conclusion: CSF concentrations of t-tau are inversely correlated to cognitive performance in patients with FTD and both t-tau and p-tau181 in AD. This study provides valuable insights into the relationship between clinical cognitive performance and tau-related pathology in FTD in comparison with AD.
Keywords: Alzheimer disease; Frontotemporal dementia; MoCA; cognition; erebrospinal fluid biomarkers.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia.Res Sq [Preprint]. 2024 Feb 13:rs.3.rs-3945509. doi: 10.21203/rs.3.rs-3945509/v2. Res Sq. 2024. PMID: 38410483 Free PMC article. Preprint.
-
FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.Neuroimage Clin. 2018 Jan 28;18:167-177. doi: 10.1016/j.nicl.2018.01.019. eCollection 2018. Neuroimage Clin. 2018. PMID: 29387532 Free PMC article.
-
Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.J Alzheimers Dis. 2015;46(2):375-80. doi: 10.3233/JAD-150069. J Alzheimers Dis. 2015. PMID: 25777512
-
Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.J Alzheimers Dis. 2018;66(2):551-563. doi: 10.3233/JAD-180409. J Alzheimers Dis. 2018. PMID: 30320576
-
Cognition Mediates the Association Between Cerebrospinal Fluid Biomarkers of Amyloid and P-Tau and Neuropsychiatric Symptoms.J Alzheimers Dis. 2024;100(3):1055-1073. doi: 10.3233/JAD-240125. J Alzheimers Dis. 2024. PMID: 38995786 Free PMC article.
References
-
- Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–2477.
-
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
-
- Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771–780.
-
- Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:131–146.
-
- Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat. 2004;24:277–295.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical